HAEMATO AG was able to achieve an EBITDA of EUR 10.0m for the fiscal year 2018 according to preliminary IFRS financial statements.
HAEMATO AG, Berlin (ISIN: DE0006190705), achieved consolidated sales of EUR 274.1m (previous year: EUR 289.4m), an operating result (EBIT) of EUR 8.5m (previous year: EUR 9.4m) and net profit of EUR 6.3m (previous year: EUR 6.96m) in the 2018 financial year, taking into account IFRS 15 “Revenues”, which must be applied from the 2018 financial year onwards.
A capital increase of EUR 5.2m to replace profit participation certificates improved the equity ratio from 57.2% (2017) to 65.0% in 2018 and contributed, among other things, to a significant reduction in financial liabilities by a total of EUR 10.9m.
After a good first half-year, the HAEMATO Group could not repeat the strong sales level of the second half-year from 2017. However, the efforts to increase the operating margin led to an improvement in gross operating profit of almost 1%.

As one of the leading suppliers of specialty pharmaceuticals, the HAEMATO Group benefits from competition in the first healthcare market. The specialisation in drugs for the treatment of chronic diseases and for individual therapies means that a positive development can be expected in the future due to demographic developments.

The earnings situation allows the Management Board to propose an unchanged dividend of 30 cents per share to the Supervisory Board.